109 related articles for article (PubMed ID: 34539853)
1. Anti-Axl monoclonal antibodies attenuate the migration of MDA-MB-231 breast cancer cells.
Chang H; An R; Li X; Lang X; Feng J; Lv M
Oncol Lett; 2021 Nov; 22(5):749. PubMed ID: 34539853
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor.
Hara T; Kimura A; Miyazaki T; Tanaka H; Morimoto M; Nakai K; Soeda J
Biochem Biophys Rep; 2020 Mar; 21():100726. PubMed ID: 32055714
[TBL] [Abstract][Full Text] [Related]
3. Engineered AXL
Duan Y; Hu B; Qiao C; Luo L; Li X; Wang J; Liu H; Zhou T; Shen B; Lv M; Feng J
Oncol Lett; 2019 Jun; 17(6):5784-5792. PubMed ID: 31186805
[TBL] [Abstract][Full Text] [Related]
4. Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment.
Tanaka M; Siemann DW
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32660000
[TBL] [Abstract][Full Text] [Related]
5. Gas6/Axl signaling pathway promotes proliferation, migration and invasion and inhibits apoptosis in A549 cells.
Wang D; Bi L; Ran J; Zhang L; Xiao N; Li X
Exp Ther Med; 2021 Nov; 22(5):1321. PubMed ID: 34630675
[TBL] [Abstract][Full Text] [Related]
6. Immune Evasion Mechanism and AXL.
Son HY; Jeong HK
Front Oncol; 2021; 11():756225. PubMed ID: 34778071
[TBL] [Abstract][Full Text] [Related]
7. AXL receptor tyrosine kinase as a therapeutic target in NSCLC.
Okimoto RA; Bivona TG
Lung Cancer (Auckl); 2015; 6():27-34. PubMed ID: 28210148
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
[TBL] [Abstract][Full Text] [Related]
9. Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.
Espindola MS; Habiel DM; Narayanan R; Jones I; Coelho AL; Murray LA; Jiang D; Noble PW; Hogaboam CM
Am J Respir Crit Care Med; 2018 Jun; 197(11):1443-1456. PubMed ID: 29634284
[TBL] [Abstract][Full Text] [Related]
10. Growth arrest-specific protein-6/AXL signaling induces preeclampsia in rats†.
Hirschi KM; Tsai KYF; Davis T; Clark JC; Knowlton MN; Bikman BT; Reynolds PR; Arroyo JA
Biol Reprod; 2020 Feb; 102(1):199-210. PubMed ID: 31347670
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Tyrosine Phosphoproteome Profiling of AXL Receptor Tyrosine Kinase Signaling Network.
Wu X; Wang L; Pearson NA; Renuse S; Cheng R; Liang Y; Mun DG; Madugundu AK; Xu Y; Gill PS; Pandey A
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439388
[TBL] [Abstract][Full Text] [Related]
12. Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD
Liu Y; Wei J; Liu J; Ma W; Duan Y; Liu D
Oncol Lett; 2021 May; 21(5):397. PubMed ID: 33777220
[TBL] [Abstract][Full Text] [Related]
13. Vitamin K2 inhibits rat vascular smooth muscle cell calcification by restoring the Gas6/Axl/Akt anti-apoptotic pathway.
Qiu C; Zheng H; Tao H; Yu W; Jiang X; Li A; Jin H; Lv A; Li H
Mol Cell Biochem; 2017 Sep; 433(1-2):149-159. PubMed ID: 28386842
[TBL] [Abstract][Full Text] [Related]
14. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
15. Biparatopic single-domain antibodies against Axl achieve ultra-high affinity through intramolecular engagement.
Henry KA; Nguyen TD; Baral TN; Hussack G; Raphael S; Arbabi-Ghahroudi M; Robert A; Durocher Y; Wu C; Jaramillo ML; MacKenzie CR
Biochem Biophys Res Commun; 2021 Jul; 562():154-161. PubMed ID: 34058562
[TBL] [Abstract][Full Text] [Related]
16. Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma.
Lee HJ; Jeng YM; Chen YL; Chung L; Yuan RH
Carcinogenesis; 2014 Apr; 35(4):769-75. PubMed ID: 24233839
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Tyro3 expression, Gas6-mediated Akt phosphorylation, and the impact of anti-Tyro3 antibodies in melanoma cell lines.
Demarest SJ; Gardner J; Vendel MC; Ailor E; Szak S; Huang F; Doern A; Tan X; Yang W; Grueneberg DA; Richards EJ; Endege WO; Harlow E; Koopman LA
Biochemistry; 2013 May; 52(18):3102-18. PubMed ID: 23570341
[TBL] [Abstract][Full Text] [Related]
18. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.
El Guerrab A; Bamdad M; Kwiatkowski F; Bignon YJ; Penault-Llorca F; Aubel C
Oncotarget; 2016 Nov; 7(45):73618-73637. PubMed ID: 27655662
[TBL] [Abstract][Full Text] [Related]
19. Gas6 expression is reduced in advanced breast cancers.
Ibrahim AM; Gray Z; Gomes AM; Myers L; Behbod F; Machado HL
NPJ Precis Oncol; 2020; 4():9. PubMed ID: 32352034
[TBL] [Abstract][Full Text] [Related]
20. Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.
Kasikara C; Davra V; Calianese D; Geng K; Spires TE; Quigley M; Wichroski M; Sriram G; Suarez-Lopez L; Yaffe MB; Kotenko SV; De Lorenzo MS; Birge RB
Cancer Res; 2019 May; 79(10):2669-2683. PubMed ID: 30877108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
